Organisation paid for research Program year 2025 Source: CMS Open Payments

Central State Research

Neither a doctor nor a teaching hospital

Research payments

$2,631,466

41 payments

Through program year 2025, Central State Research is reported as receiving $2,631,466 in research payments, across 41 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $417,945 13
2024 Research $778,586 10
2023 Research $718,648 7
2022 Research $292,954 4
2021 Research $368,258 5
2020 Research $44,775 1
2019 Research $10,300 1

Breakdown

Who paid Research payments · program years 2019–2025
  1. Eli Lilly and Company $2,631,466 41 payments
Studies the money was for Research payments · program years 2019–2025
  1. Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimers Disease $762,223 7 payments
  2. A Study of Daily Oral Orforglipron (Ly3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity Or Overweight at Increased Cardiovascular Risk (Achieve-4) $449,172 4 payments
  3. A Study of Donanemab (Ly3002813) in Participants With Early Alzheimer's Disease (Trailblazer-Alz 2) $418,356 2 payments
  4. A Phase 3, Randomized, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Retatrutide Once Weekly Compared With Semaglutide Once Weekly in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With Or Without Sglt2 Inhibitor (Transcend-T2d-2) $333,391 4 payments
  5. A Study of Daily Oral Orforglipron (Ly3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity Or Overweight at Increased Cardiovascular Risk (Achieve-4) $206,227 2 payments
  6. A Study of Donanemab Versus Placebo in Participants at Risk for Cognitive and Functional Decline of Alzheimer's Disease $157,759 6 payments
  7. A Phase 3, Randomized, Multicenter, Double-Blind Study to Investigate the Efficacy and Safety of Retatrutide Once Weekly Compared With Placebo in Adult Participants With Type 2 Diabetes, Moderate Or Severe Renal Impairment With Inadequate Glycemic Control on Basal Insulin With Or Without Metformin And/Or Sglt2 Inhibitor $118,233 4 payments
  8. A Donanemab (Ly3002813) Prevention Study in Participants With Alzheimer's Disease (Trailblazer-Alz 3) $93,896 2 payments
  9. Anti-Amyloid Treatment in Asymptomatic Alzheimers Disease -A4 Study $55,075 2 payments
  10. A Study of Donanemab Versus Placebo in Participants at Risk for Cognitive and Functional Decline of Alzheimer's Disease $11,984 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record